ANCHOR Check - Eli Lilly (LLY)

Lilly is a regulated molecule factory with patents, trials, plants, prescribers, payer relationships, and one of the most important cardiometabolic franchises on earth.

ANCHOR says durable.

Not hype-proof. Not price-proof. Durable.

Badge: ABIP ANCHOR Certified

Gates:

The moat is not “AI drug discovery.”

The moat is approved molecules, regulatory data, compound patents, high-friction manufacturing, physician trust, payer access, and the ability to turn chronic disease demand into global supply.

The weak point is price.

Lilly has monster volume. It is already giving back realized price.

The market sees Lilly as the GLP-1 company.

That is not wrong.

In 2025, Lilly revenue grew 45% to $65.2 billion. Mounjaro did $23.0 billion. Zepbound did $13.5 billion. In Q1 2026, revenue grew 56% to $19.8 billion, with Mounjaro at $8.7 billion and Zepbound at $4.2 billion. Lilly raised 2026 revenue guidance to $82–$85 billion.

That is not vibes.

That is product pull.

But the part people skip is the price line. Q1 growth came with lower realized prices from Mounjaro and Zepbound. The company also says obesity access depends on payer coverage, employer opt-ins, government programs, and cash-pay behavior.

Volume is the story.

Access is the choke point.

AI can help Lilly screen targets, design trials, forecast demand, monitor safety signals, automate paperwork, and tighten commercial execution.

Good.

But Lilly’s bottleneck is not a spreadsheet.

It is clinical proof.

It is FDA approval.

It is manufacturing capacity.

It is fill-finish.

It is device assembly.

It is quality systems.

It is formulary placement.

It is government pricing.

It is whether patients stay on therapy.

Lilly’s own 10-K says shifting or adding pharmaceutical manufacturing capacity is lengthy, capital-intensive, process-heavy, and requires regulatory approvals. That is the whole point. Software compresses cognition. It does not compress regulated capacity into existence.

A — Asset-Embedded: 8/10
Lilly is embedded in the real healthcare stack: FDA labels, clinical data, prescriber behavior, pharmacies, payer contracts, manufacturing sites, supply chains, and patient adherence loops.

This is not a lightweight app sitting on top of demand. This is regulated infrastructure for chronic disease.

Mounjaro/Zepbound also have compound patent protection listed into 2036 in the U.S., with longer dates in major markets like Europe and Japan. That matters.

N — Non-Discretionary: 8/10
Diabetes care is non-discretionary.

Obesity treatment is more complicated. The disease is real. The demand is real. But access is still mediated by insurance, employers, Medicare rules, pricing, and patient ability to pay.

That keeps this from a 10.

Medicare’s GLP-1 Bridge program now covers Foundayo and Zepbound KwikPen for eligible patients at $50 per month, which expands access. It also makes Lilly more exposed to public reimbursement politics.

C — Capital-Intensive: 10/10
This is exactly what capital intensity looks like.

Lilly spent $13.3 billion on R&D in 2025. Long-lived asset expenditures were $8.7 billion. It is expanding manufacturing capacity across multiple U.S. and international sites.

AI can make parts of the machine smarter.

It does not remove the machine.

H — Hard to Replace: 8/10
Hard to replace does not mean impossible to compete with.

Novo is real. Biosimilars are real. China-based competition is real. Mass-compounded and counterfeit incretins are real risks. Lilly says technological innovation is amplifying competition in drug discovery and healthcare delivery models.

Still, replacing Lilly requires more than a better model.

You need approved drugs, safety data, manufacturing, prescriber trust, supply reliability, payer access, and global commercialization.

That is a brutal stack.

O — Obsolescence-Resistant: 8/10
AI does not make tirzepatide obsolete by itself.

A better drug can.

A safer oral can.

A cheaper competitor can.

A payer decision can.

A safety signal can.

But AI alone does not erase clinical outcomes, regulatory approvals, or manufacturing rights. Lilly’s Foundayo approval shows the next layer: oral GLP-1s are coming, but they still need trials, labels, dosing, warnings, and real-world adoption.

R — Real-World Demand: 9/10
This is real-world demand with cash registers attached.

Mounjaro and Zepbound are already multibillion-dollar quarterly products. The demand is tied to diabetes, obesity, cardiovascular risk, sleep apnea, and broader metabolic disease.

The main question is not whether demand exists.

It is who pays, at what price, and for how long.

Pricing pressure is the biggest risk.

Lilly can grow scripts and still lose economic power if payers, governments, employers, or cash-pay competition force realized prices down faster than volume rises.

Manufacturing is the second risk.

The company needs capacity to show up on time, pass regulatory qualification, and match demand without creating shortages or overbuilding into future price compression.

Safety and litigation matter.

Lilly disclosed product liability litigation involving incretin medicines including Mounjaro, Trulicity, and Zepbound, with MDLs focused on alleged gastrointestinal injuries and NAION claims.

Competition matters.

Novo, oral GLP-1s, next-gen incretins, China-based R&D, generics, biosimilars, and Lilly’s own pipeline can all pressure today’s products.

Access matters.

Obesity demand is huge, but coverage is still a knife fight.

If I’m right:
Lilly stays one of the rare AI-era public companies where the core bottleneck is still physical, regulated, clinical, and trust-based. AI improves the operating model, but the value remains anchored in drugs, data, manufacturing, and access.

If I’m wrong:
The analysis is too bullish if realized prices collapse faster than volume scales, safety issues widen, manufacturing misses, or competitors bring materially better obesity and diabetes drugs to market faster than Lilly can defend.

What would change my mind:
Sustained GLP-1 price erosion without matching volume growth. Major payer pullback. Evidence that oral competitors are taking share without margin damage to the category. New safety data that changes prescribing behavior. Manufacturing expansion delays that cap demand capture.

AI is a tool for Lilly.

It can improve discovery, trial operations, manufacturing planning, pharmacovigilance, and commercial execution.

But it also lowers the cost of trying to compete. More shots on goal. More biotech velocity. More global pressure.

The moat is not AI.

The moat is what still has to happen after the model gives you an idea.

AI can suggest the target.

It can’t run the molecule through trials, plants, payers, pharmacies, and patients.

— Connor
Alpha Before It Prints

🔗 Click to Connect with me

© 2026 Alpha Before It Prints
Unsubscribe